Trial reportPediatric blood & cancer2026
Feasibility Trial of a Tailored Adherence-Promotion Intervention for Adolescents and Young Adults With Cancer.
Trial report in Pediatric blood & cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05706610 (A Pilot Feasibility Trial of a Tailored Intervention to Improve Adherence in Adolescents and Young Adults With Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Feasibility Trial of a Tailored Intervention to Improve Adherence in Adolescents and Young Adults With Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundAdherence to cancer treatment protocol medications is critical for optimizing health outcomes, but up to 60% of adolescents and young adults (AYAs) with cancer miss doses. This randomized pilot trial evaluated the feasibility, usability, and acceptability of a tailored adherence-promotion intervention (Supporting Medication Management with Individualized Treatment, SUMMIT) for AYAs with cancer.
methodsSeventy AYAs (ages 15-24 years) prescribed an oral chemotherapy or a prophylactic antimicrobial as part of their cancer treatment regimen enrolled in the trial. Of these, 24 met criteria for randomization and were assigned to the intervention (SUMMIT) or control (uniform standard of care) arm. Feasibility data were tracked prospectively. AYAs completed usability and acceptability measures and stored their medication in an electronic adherence monitoring device. Descriptive statistics were used to evaluate achievement of feasibility thresholds. An analysis of covariance (ANCOVA) and a logistic regression were used to explore group differences in electronically monitored adherence.
resultsEnrollment (70/77 = 91%), retention (56/65 = 86%), fidelity (100%), and assessment completion (100%) rates exceeded thresholds. The intervention was rated as usable and acceptable. Compared to those randomized to the control arm, AYAs randomized to SUMMIT had 18% higher post-intervention adherence (95% confidence interval [CI] = 3.56, 32.35) and were 12 times more likely to improve their adherence by 10% or more from pre- to post-intervention (odds ratio = 12.00, 95% CI = 1.51, 95.53).
conclusionsFeasibility, acceptability, and usability data are promising, and results suggest this tailored adherence-promotion intervention has the potential to increase medication adherence among AYAs with cancer.
trial registrationClinicalTrials.gov Registration: NCT05706610.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.